Dr. Lacey has dedicated years to researching the potential benefits of psychedelics for mood disorders. His approval by New Zealand's health ministry underscores his vast experience with psilocybin during previous clinical trials. The decision comes in light of the increasing number of patients who have not responded positively to traditional antidepressant therapies.

To ensure safety and efficacy, the New Zealand government has outlined stringent regulations surrounding psilocybin treatments. Patients will not be given unfettered access to the substance; rather, they must undergo three preliminary talk therapy sessions before receiving their doses. During the treatment, patients will ingest a controlled amount of psilocybin while comfortably reclined and listening to soothing sounds, including nature noises and traditional Māori music, creating an immersive therapeutic experience that lasts approximately eight hours.

The move to incorporate psilocybin into therapeutic practices highlights a growing acceptance and scientific inquiry into alternative mental health treatments, gradually moving psychedelics from the shadows into mainstream medicine.